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ABSTRACT
Inhibiting the nuclear protein MYC involved in the majority of human cancers has long been considered
an impossible mission and several technical challenges have discouraged the development of MYC
inhibitory strategies. Nevertheless, in our recent publication in Science Translational Medicine “Intrinsic
cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy”, we
demonstrate for the first time the feasibility of pharmacological MYC inhibition in vitro and in vivo
using an Omomyc-based mini-protein.
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Let’s be honest: working in cancer research is both a blessing
and a curse. On one hand, one feels that we are fighting the
good fight, looking for the ideal cancer drug that will poten-
tially spare the lives of millions of people; on the other, the
fight seems unfair, against an impossible enemy that displays
the capacity to develop resistance to whichever therapy we
come up with. Can we do better than that?
The answer to this question might be found by redefining our
concept of the ideal cancer drug. We can all agree, for example,
that such a drug should target a non-redundant function in
cancer cells, ideally essential only for tumor cells but not for
normal tissues. However, the majority of our targets so far are
instead in the most redundant compartments of cells and path-
ways that can quickly rewire to compensate for our attacks.
Current approaches should not be dismissed and it is apparent
that, in many instances, they have led to a significant degree of
success, especially in personalized medicine, which is clearly
effective at least in a certain percentage of patients.
Nevertheless, these approaches can be complemented by alter-
natives. Novel opportunities, for instance, might lie in the iden-
tification of central, less evolutionarily degenerate nodes in
cancer, which might be non-redundant and offer unprecedented
therapeutic strategies not yet explored. Some of these functions
might be identified, for example, in the nuclei of cells (a com-
partment less accessible to standard drugs) and fall into the
category of transcription factors, master regulators of the onco-
genic programs that can contribute to the cancer phenotype.
Among those, an even more challenging group is represented by
intrinsically disordered proteins, which lack a defined three-
dimensional structure amenable to attack by canonical small
molecule inhibitors.
But are these challenges sufficient to dismiss these targets
as “undruggable”? Our answer is definitely not. In our last
publication in Science Translational Medicine,1 we pre-
clinically established the feasibility of pharmacologically tar-
geting MYC – not only a well-characterized central node in
cancer but also a nuclear transcription factor and intrinsically
disordered protein2 – by making use of a cell-penetrating
polypeptide called Omomyc.
MYC is known to be deregulated in the majority of cancers,
either following gene amplification ormutation ofmany upstream
signalling pathways – the Kirsten RAt Sarcoma GTPase (com-
monly known as KRAS), Phosphatidylinositol-3 Kinase (PI3K),
Wingless-related integration protein (better known as WNT),
etc. – which can lead to steady, non-stop MYC function.2 Many
studies have now clearly established the therapeutic utility of
targeting MYC for cancer treatment.3 However, as MYC is essen-
tial during embryonic development and for normal function of
proliferative tissues, dramatic side effects were expected from its
complete inhibition. Previous strategies to drug MYC have
attempted to inhibit it at many levels, from transcription to
translation, or even protein stability.3 In the few cases in which
some of these attempts have reached the clinic, they have been
discontinued due to evidence of toxicity. Interestingly, though,
this clinical toxicity did not seem to arise directly from the MYC
blockade, but because of the use of ineffective inhibitory strategies
and lack of specificity for the target. In this respect, our proposed
therapeutic mini-protein approach is different.
The MYC transcription factor is composed of a DNA binding
and dimerization domain (DBD) and a transactivation domain
(TA). In order to function,MYCmust formheterodimers with the
MYC associated factor X (better known as MAX), its obligate
partner, which enables binding to Enhancer box (E-box) DNA
sequences. We previously designed Omomyc, a MYC-dominant
negative consisting of the DBD of MYC containing four amino
acidicmutations. Thanks to thesemutations and its altered dimer-
ization properties compared to the wild type DBD of MYC,
Omomyc is able to both inhibit MYC/MAX interaction and
their binding to DNA. In fact, not only can Omomyc sequester
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MYC in dimers unable to recognize the E-box, it can also compete
for MYC/MAX DNA binding in the form of Om
omyc/Omomyc homodimers or Omomyc/MAX heterodimers.4
Omomyc was initially used in vivo in its transgenic form to
establish for the first time the therapeutic potential of MYC
inhibition to stop tumor progression, and even led to tumor
eradication, while also providing validation of its safety inmultiple
mouse models of cancer, independently of their tissue of origin or
driving oncogenic lesions.5–8 Despite this undisputable therapeu-
tic opportunity, though,Omomycwas deemed too bulky and unfit
to ever become a drug.9
And this is where our last publication is really proving this
assumption wrong. Cell-penetrating peptides (CPPs), also
known as protein transduction domains, have the ability to
allow intracellular delivery of multiple cargos,10 and have
recently received considerable attention because of their high
transduction efficiency and low cytotoxicity. In Beaulieu et al.,
2019,1 making use of a purified, recombinantly produced
Omomyc polypeptide, we demonstrated for the first time that
Omomyc’s basic region is a CPP itself. Treating several cancer
cell lines with increasing concentrations of fluorescently labeled
Omomyc, we were able to observe internalization of the protein
and partial localization in the nuclei at concentrations as low as
0.3 μM, causing growth arrest with an IC50 in the low micro-
molar range. We also confirmed that the mini-protein acted as
its transgenic counterpart, being able to form Omomyc/MYC
heterodimers, incapable of DNA binding, as well as Omomyc/
Omomyc homodimers and Omomyc/MAX heterodimers, dis-
playing instead DNA binding ability. All these dimers putatively
contribute to MYC displacement from ~98% of its genomic
locations. The displacement of MYC from its target promoters
results in a marked transcriptional reprogramming of cancer
cells, especially evident as reversion of the expression of MYC-
related gene signatures.
Our results in vitro prompted us to assess the Omomyc
mini-protein’s therapeutic utility in a mouse model of
KRas-driven Non-Small-Cell lung cancer (NSCLC). Our
first attempt was through intranasal administration of the
polypeptide, three times per week, at a dose of 2.37 mg/
kg. A 4-week treatment prevented tumor progression and
caused regression to a lower tumor grade, as
a consequence of both reduced proliferation and
increased cell death (Figure 1). Following Omomyc treat-
ment, we also observed recruitment of intratumoral
T cells, in line with the observed transcriptional repro-
gramming of cytokines and chemokines gene sets.
Similar results were also obtained with intravenously admi-
nistered Omomyc mini-protein to mice carrying xenografts of
human NSCLC H1975 cells, which are EGFR (epidermal
growth factor receptor), PI3K and P53 (tumor protein TP53)
mutant, in addition to being resistant to erlotinib. Also in this
case, Omomyc treatment significantly reduced tumor
Figure 1. Proof of concept of the pharmacological application of the Omomyc mini-protein as a therapeutic for the treatment of Non-Small-Cell Lung Cancer
(NSCLC). The Omomyc mini-protein was administered intranasally (on the left) in a mouse model of KRAS-driven NSCLC and intravenously (on the right) in
a xenograft model of human NSCLC H1975 cells, where it was either used alone or in combination with paclitaxel (PTX), considered in this case as standard of care
(SOC).
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progression. Moreover, when given in combination with
paclitaxel (PTX), Omomyc had a higher therapeutic impact,
significantly extending the survival of the animals. (Figure 1)
Overall, our results provide the first evidence and preclinical
validation of the Omomyc mini-protein as a specific pharmaco-
logical MYC inhibitor and excellent candidate for clinical devel-
opment. Themolecule is predicted to reach clinical trials in 2020.
Importantly, our paper1 also provides the proof of concept
for the use of therapeutic polypeptides to inhibit a well-known
difficult-to-target protein such as MYC, suggesting that
a similar approach might be extended to other challenging
targets within cancer cells.
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